Assessment of Chilbains Occuring During Covid-19 Infection
ChilblainCOVID
Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains
1 other identifier
observational
30
1 country
1
Brief Summary
Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. These acral manifestation could be due to a direct viral effect, but also to microthrombosis or vascularitis. Understanding the pathomechanisms involved could provide interesting clue for understanding not only the skin manifestations but also some of the other systemic symptoms associated to covid-19 infection. This study plan to characterize these acral manifestations by analyzing the clinical and dermoscopic patterns and to correlate them with the non-invasive vascular explorations but also immune and coagulopathy explorations that are done in the CHU of Nice in covid-19 patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 9, 2020
CompletedStudy Start
First participant enrolled
April 9, 2020
CompletedFirst Posted
Study publicly available on registry
April 14, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 25, 2027
ExpectedJune 29, 2026
June 1, 2026
1.1 years
April 9, 2020
June 25, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Clinical skin manifestations
Type and description of the skin manifestations with a special focus on patients with chilblains
3 months
Secondary Outcomes (2)
Histology and biological data
3 months
Non invasive vascular examination
3 months
Eligibility Criteria
All patients with covid infection presenting with skin manifestations
You may qualify if:
- All patients with proven covid infection (using PCR, serum antibody or lung TDM) and presenting at least one cutaneous lesions that occurred during the infection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de Nice
Nice, 06200, France
Related Publications (1)
Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, Giordanengo V, Gonfrier G, Raimondi V, Bausset O, Adjtoutah Z, Garnier M, Burel-Vandenbos F, Dadone-Montaudie B, Fassbender V, Palladini A, Courjon J, Mondain V, Contenti J, Dellamonica J, Leftheriotis G, Passeron T. Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic. JAMA Dermatol. 2021 Feb 1;157(2):202-206. doi: 10.1001/jamadermatol.2020.4324.
PMID: 33237291DERIVED
Biospecimen
Serum, skin biopsy, urine
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 9, 2020
First Posted
April 14, 2020
Study Start
April 9, 2020
Primary Completion
April 30, 2021
Study Completion (Estimated)
June 25, 2027
Last Updated
June 29, 2026
Record last verified: 2026-06